Seen in the press: Nemera’s article featured in ‘Drug Development Delivery’

Seen in the press: Nemera’s article featured in ‘Drug Development Delivery’

“Drug Development Delivery” magazine published an article about the drug delivery impact of design adjustment of Autoinjector. 

The recently published “Drug Development Delivery” magazine includes an article about Nemera: “Autoinjector design adjustment to control needle insertion & initial injection speed – could this positively impact drug delivery?”.

In this article, Severine Duband, Global Category Manager in the parenteral field, Pascal Durand, Technology Product Manager and Thomas Regard, Design engineer, speak about the impact of autoinjector design adjustement on the drug delivery.

A majority of the new drugs in the pipelines of pharmaceutical companies are so-called “biologics.” These new biologic drugs, such as monoclonal antibodies (mAbs), are very good candidates for the treatment of the aforementioned chronic diseases.

Biological drugs are very often needed in high concentration: this can be driven by the nature of the molecule, composition of the final drug, and by the effort to decrease the frequency of treatment for the patient. Their viscosity increases as power law of the antibody concentration. Thus, to be injected, these molecules need to be diluted, which leads to higher injection volumes, and lower (but still high) viscosity. As a result, larger dose drug deliveries are a growing segment, with volume shifting toward 2 ml.

image article DDD

Usage of higher energy level to deliver viscous formula- tions could result in higher shocks on the syringe, especially at the end of syringe insertion and start of syringe emptying, and consequently increases the risk of glass syringe breakage.

Controlling the needle insertion speed can reduce the shock on the prefilled syringe. Lowering this shock will reduce the risk of glass breakage, and will allow a smooth transition to syringe emptying. Also, it was demonstrated that pressure waves generated from device actuation could lead to glass breakage.3 Reducing the syringe speed contributes to the reduction of the pressure waves, reducing then the risk of glass breakage.

We conduct a study with different objectives:

  • to develop a calculation method for needle insertion speed and energy level transmitted to the syringe
  • to use our calculation method to im- prove injection devices allowing smooth transition between needle insertion and syringe emptying, especially for large dose, viscous formulations, and thin needles
  • to validate our calculation method and our improved injection device by experimental measurements

To learn more about this study, you can read the full article. 

The full article:

The full issue of the magazine:

About Nemera

Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology & generics industries.

Nemera’s services and products cover several key delivery routes: Ophthalmic, Nasal, Buccal, Auricular, Inhalation, Dermal/Transdermal and Parenteral.

Nemera always puts patients first, providing the most comprehensive range of devices in the industry, including off-the-shelf innovative systems, customized design development and contract manufacturing.